<DOC>
	<DOCNO>NCT00560378</DOCNO>
	<brief_summary>Patients participate previous study Tacrolimus ointment atopic eczema entitle enter four-year follow study investigate safety treatment Tacrolimus ointment 0.1 %</brief_summary>
	<brief_title>Long-term Safety Protopic Atopic Eczema</brief_title>
	<detailed_description>A long-term , multi-centre , open label , non-comparative phase III study patient atopic dermatitis . All centre Europe participate still participate FG-506-06-12 , FG-506-06-18 FG-506-06-19 , FG-506-06-22 FG-506-06-23 study offer participation protocol . Only patient enrol centre mention study , receive least one dose study medication enrol . Tacrolimus ointment 0.1 % administered clearance skin occur . Treatment restart sign symptom reoccur . Safety assess adverse event report patient/parent/guardian observed investigator site application elsewhere . The safety evaluation include monitor routine hematology serum chemistry parameter Baseline/Day 1 , Week 1 , Month 6 , Month 12 , Month 18 , Month 24 , Month 30 , Month 36 , Month 42 and/or end study ( End-of-Study Visit ) .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Every patient participate FG5060612 , FG5060618 , FG5060619 , FG5060622 FG5060623 study , receive least one dose study medication Patient likely benefit treatment Tacrolimus ( FK506 ) ointment opinion investigator Patient atopic dermatitis Body surface involvement 5 % 60 % patient age 2 year 15 year ( reach 16th birthday ) 5 % 100 % patient 16 year age old Patient infection require treatment Patient know HIV positive Patient systemic disease , include cancer history cancer AIDS , would contraindicate use Tacrolimus ( FK506 ) ointment</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Administration , topical</keyword>
	<keyword>Drug safety</keyword>
	<keyword>Adults</keyword>
	<keyword>Children</keyword>
</DOC>